Department of Molecular and Developmental Genetics, VIB, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Clin Cancer Res. 2011 Oct 15;17(20):6381-6. doi: 10.1158/1078-0432.CCR-10-3037. Epub 2011 Jun 24.
The TLX1 transcription factor oncogene is frequently activated by chromosomal translocations in T-cell acute lymphoblastic leukemia (T-ALL) and defines a distinct molecular group of tumors characterized by differentiation arrest at the early cortical stage of thymocyte differentiation and excellent response to therapy. Recent developments from the analysis of genomic data on TLX1-specific transcriptional targets and analysis of the molecular mechanisms of TLX1 transformation in human- and mouse-induced leukemias have shown novel insight into the activity of this transcription factor oncogene. Aberrant expression of TLX1 in T-cell progenitors disrupts normal T-cell development and triggers the development of aneuploidy during T-cell transformation. Importantly, the disruption of the mitotic checkpoint in TLX1-induced tumors may be linked not only to the acquisition of secondary genetic alterations in T-ALL but also to increased sensitivity of these tumors to chemotherapy with drugs targeting the formation of the mitotic spindle.
TLX1 转录因子癌基因在 T 细胞急性淋巴细胞白血病(T-ALL)中经常通过染色体易位激活,并定义了一个独特的分子肿瘤群体,其特征是在胸腺细胞分化的早期皮质阶段分化停滞,对治疗有极好的反应。最近对 TLX1 特异性转录靶点的基因组数据分析和对人源和鼠源诱导白血病中 TLX1 转化的分子机制的分析,揭示了这种转录因子癌基因的新活动。TLX1 在 T 细胞前体细胞中的异常表达破坏了正常的 T 细胞发育,并在 T 细胞转化过程中引发非整倍体的发生。重要的是,TLX1 诱导的肿瘤中有丝分裂检查点的破坏不仅与 T-ALL 中获得继发性遗传改变有关,而且与这些肿瘤对针对有丝分裂纺锤体形成的化疗药物的敏感性增加有关。